CSL Ltd (CSL)

Currency in AUD
197.29
-2.56(-1.28%)
Closed·
CSL is included in our AI-picked strategies. See how they work
Fair Value
Day's Range
194.56199.51
52 wk Range
90.00205.48
Key Statistics
Bid/Ask
196.50 / 197.50
Prev. Close
199.85
Open
197.69
Day's Range
194.56-199.51
52 wk Range
90-205.48
Volume
1.53M
Average Vol. (3m)
1.1M
1-Year Change
10.3103%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CSL Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
203.29
Upside
+3.04%
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 4 consecutive years

CSL Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell

Analyst Ratings

8 Buy
8 Hold
1 Sell
Ratings:
17 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 203.29
(+3.04% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
UBS
Buy225.00+14.05%181.00MaintainOct 30, 2026
CLSA
Buy215.00+8.98%180.00MaintainOct 22, 2026
Citi
Hold180.00-8.76%160.00MaintainOct 08, 2026
Goldman Sachs
Buy182.50-7.50%163.60MaintainSep 28, 2026
CLSA
Buy180.00-8.76%-MaintainSep 21, 2026

CSL Ltd Earnings Call Summary for H2/2026

  • CSL reported FY26 revenue of $15.8B (down 1%) and underlying NPAT-A of $3.1B (down 2%); statutory loss of $2.6B due to $6B in restructuring charges.
  • Shares surged 16.4% to $156.68 as company guided FY27 NPAT growth of ~5% despite flat revenue; authorized new AUD 1.1B buyback program.
  • CSL Behring expected to return to mid-single-digit growth on strong immunoglobulin demand; Vifor remains major drag with ~25% revenue decline forecast.
  • Company targeting $220M incremental savings in FY27, rising to $550M by FY28; maintaining dividend at $2.92/share with strong $3.5B operating cash flow.
  • Seqirus forecast for low-single-digit growth despite soft U.S. flu market; management emphasized plasma efficiency and portfolio simplification as key priorities.
Last Updated: 08/17/2026, 09:27 PM
Read Full Transcript
CSL investor slides for H2/2026
CSL FY26 slides
Last Update: Aug 18, 2026
See full investor slides

Earnings

Latest Release
Aug 18, 2025
EPS / Forecast
2.04 / 2.70
Revenue / Forecast
7.08B / 10.2B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS -7.73
Dividend Yield
2.05%
Industry Median 2.11%
Annualized Payout
4.05
Paid unevenly
5-Years Growth
+5.63%
Growth Streak

CSL Income Statement

Compare CSL to Peers and Sector

Metrics to compare
CSL
Peers
Sector
Relationship
P/E Ratio
−24.3x16.4x−0.2x
PEG Ratio
0.130.060.00
Price / Book
4.2x2.5x2.6x
Price / LTM Sales
4.0x2.1x2.6x
Upside (Analyst Target)
3.2%21.0%76.9%
Fair Value Upside
Unlock18.9%14.9%Unlock

CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. The company’s therapeutic areas includes Immunoglobulins, Immunology, Immunology Haematology, Cardiovascular and Renal, and Vaccines. It also licenses CSL intellectual property. It also develops vaccines for the prevention of infectious disease. The company has strategic collaboration with Dutch biotech company VarmX BV for the development of VMX-C001 to help restore blood coagulation in patients requiring urgent surgery; and Alentis Therapeutics AG to develop and commercialise lixudebart for rare kidney and liver diseases. The company was formerly known as Commonwealth Serum Laboratories Limited and later changed its name to CSL Limited in October 1991. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

Employees
29000
Market
Australia

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
115.68M24.15%22.82B
Other Institutional Investors
78.13M16.31%15.41B
Public Companies & Retail Investors
285.11M59.53%56.25B
Total
478.91M100.00%94.48B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
State Street Investment Management8.24%39,466,3837,786,323
BlackRock, Inc.6.98%33,446,6876,598,697

People Also Watch

13.440
FMG
+2.13%
29.920
WDS
-0.89%
88.91
ANT
-8.50%

FAQ

What Is the CSL (CSL) Stock Price Today?

The CSL stock price today is 197.29 AUD.

What Stock Exchange Does CSL Trade On?

CSL is listed and trades on the Sydney Stock Exchange.

What Is the Stock Symbol for CSL?

The stock symbol for CSL is "CSL."

Does CSL Pay Dividends? What’s The Current Dividend Yield?

The CSL dividend yield is 2.1%%.

What Is the CSL Market Cap?

As of today, CSL market cap is 94.48B AUD.

What Is CSL's Earnings Per Share (TTM)?

The CSL EPS (TTM) is -7.73.

From a Technical Analysis Perspective, Is CSL a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has CSL Stock Split?

CSL has split 1 times.

How Many Employees Does CSL Have?

CSL has 29000 employees.

What is the current trading status of CSL (CSL)?

As of Nov 22, 2026, CSL (CSL) is trading at a price of 197.29 AUD, with a previous close of 199.85 AUD. The stock has fluctuated within a day range of 194.56 AUD to 199.51 AUD, while its 52-week range spans from 90.00 AUD to 205.48 AUD.

What Is CSL (CSL) Price Target According to Analysts?

The average 12-month price target for CSL is 203.29 AUD, with a high estimate of 239.23123395 AUD and a low estimate of 161.09802145 AUD. 8 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +3.04% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.